RESUMO
The two major determining factors for Alzheimer's disease (AD) are genetics and lifestyle. Alleles of the apolipoprotein E (APOE) gene play important roles in the development of late-onset AD, with APOEÉ4 increasing risk, APOEÉ3 being neutral, and APOEÉ2 reducing risk. Several modifiable lifestyle factors have been studied in terms of how they can modify the risk of AD. Among these factors are dietary pattern, nutritional supplements such as omega-3 fatty acids, and B vitamins, physical exercise, and obesity, and vitamin D. The Western diet increases risk of AD, while dietary patterns such as the Mediterranean and vegetarian/vegan diets reduce risk. Foods associated with reduced risk include coffee, fruits and vegetables, whole grains and legumes, and fish, while meat and ultraprocessed foods are associated with increased risk, especially when they lead to obesity. In multi-country ecological studies, the amount of meat in the national diet has the highest correlation with risk of AD. The history of research regarding dietary patterns on risk of AD is emphasized in this review. The risk of AD can be modified starting at least by mid-life. People with greater genetic risk for AD would benefit more by choosing lifestyle factors to reduce and/or delay incidence of AD.
Assuntos
Doença de Alzheimer , Dieta , Estilo de Vida , Humanos , Doença de Alzheimer/genética , Doença de Alzheimer/epidemiologia , Doença de Alzheimer/história , Fatores de Risco , Apolipoproteínas E/genética , Predisposição Genética para DoençaRESUMO
Despite myriad technological advances in neuroscience, the nervous system harbors morphological phenomena that continue to defy explanation. First described by the classical microscopists, including Santiago Ramon y Cajal, at the end of the 19th century, the neuronal intranuclear rodlet (INR) has mystified neurohistologists and microscopists for centuries. In this review article, we will provide an overview of the discovery of the INR as well as the subsequent attempts to elucidate its nature and functional significance. We outline our own studies of this structure over the past three decades, focusing on its elusive nature, its interactions with other nuclear organelles, and on disease-related quantitative changes in Alzheimer's disease. We then describe our somewhat serendipitous discovery that these structures are filamentous aggregates of the nucleotide-synthesizing metabolic enzyme inosine monophosphate dehydrogenase. The filamentation of metabolic enzymes to form mesoscale cellular structures called "rods and rings" or "cytoophidia" (Greek for "cellular snakes") is a recently described phenomenon that remains to be systematically investigated in the nervous system. Thus, this review provides an intriguing historical juxtaposition in neuroscience, inculcating the neuronal INR, once a mere morphological curiosity, into one of the most rapidly evolving fields in contemporary cell biology.
Assuntos
Neurônios , Humanos , Animais , Corpos de Inclusão Intranuclear/metabolismo , Doença de Alzheimer/história , Doença de Alzheimer/patologia , História do Século XXRESUMO
In celebration of the National Institute on Aging's (NIA) 50th anniversary, this paper highlights the significant advances in cognitive aging research and the promotion of cognitive health among older adults. Since its inception in 1974, the NIA has played a pivotal role in understanding cognitive aging, including cognitive epidemiology, interventions, and methods, for measuring cognitive change. Key milestones include the shift toward understanding cognitive impairment and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), the development of large-scale longitudinal studies, and the incorporation of AD/ADRD-related biomarkers in cognitive aging cohorts. Additionally, NIA has championed diversifying the scientific workforce through initiatives, such as the Resource Centers for Minority Aging Research and the Butler-Williams Scholars Program. The next 50 years will continue to emphasize the importance of inclusion, innovation, and impactful research to enhance the cognitive health and well-being of older adults.
Assuntos
Aniversários e Eventos Especiais , Envelhecimento Cognitivo , National Institute on Aging (U.S.) , Humanos , Envelhecimento Cognitivo/psicologia , Estados Unidos/epidemiologia , Idoso , História do Século XXI , História do Século XX , Pesquisa Biomédica/história , Pesquisa Biomédica/tendências , Disfunção Cognitiva , Doença de Alzheimer/história , Doença de Alzheimer/psicologia , Envelhecimento/psicologiaRESUMO
Aging is the main risk for neurodegenerative disorders like Alzheimer's disease. In this short review, I will comment on how delaying brain aging through the addition of Yamanaka Factors or small compounds that bind to the folate receptor alpha, which promote the expression of the Yamanaka Factors or by the decrease tau levels in brain cells from older subjects could serve as strategies to prevent Alzheimer's disease.
Assuntos
Envelhecimento , Doença de Alzheimer , Encéfalo , Proteínas tau , Humanos , Doença de Alzheimer/prevenção & controle , Doença de Alzheimer/metabolismo , Doença de Alzheimer/história , Proteínas tau/metabolismo , Encéfalo/metabolismo , Encéfalo/patologia , Animais , História do Século XX , História do Século XXIRESUMO
This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.
Assuntos
Doença de Alzheimer , Doença de Alzheimer/história , Humanos , Neurologistas/história , MasculinoRESUMO
Treatment of Alzheimer's Disease (AD) remains an unsolved issue despite the pronounced global attention it has received from researchers over the last four decades. Determining the primary cause of the disease is challenging due to its long prodromal phase and multifactorial etiology. Regardless, academic disagreements amongst the scientific community have helped in making significant advancements in underpinning the molecular basis of disease pathogenesis. Substantial development in fluid and imaging biomarkers for AD led to a sharp turn in defining the disease as a molecular construct, dispensing its clinical definition. With conceptual progress, revisions in the diagnostic criteria of AD were made, culminating into the research framework proposed by National Institute on Aging and Alzheimer's Association in 2018 which unified different stages of the disease continuum, giving a common language of AT(N)1 classification to researchers. With realization that dementia is the final stage of AD spectrum, its early diagnosis by means of cerebrospinal fluid biomarkers, Positron Emission Tomography and Magnetic Resonance Imaging of the brain holds crucial importance in discovering ways of halting the disease progression. This article maps the insights into the pathogenesis as well as the diagnostic criteria and tests for AD as these have evolved over time. A contextualized timeline of how the understanding of AD has matured with advancing knowledge allows future research to be directed and unexplored avenues to be prioritized.
Assuntos
Doença de Alzheimer/história , História do Século XX , História do Século XXI , HumanosAssuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/metabolismo , Amiloide/ultraestrutura , Doença de Alzheimer/história , Doença de Alzheimer/patologia , Amiloide/química , Microscopia Crioeletrônica/história , Microscopia Crioeletrônica/instrumentação , História do Século XX , História do Século XXI , Humanos , Espectroscopia de Ressonância Magnética/história , Espectroscopia de Ressonância Magnética/instrumentação , Conformação Proteica em Folha betaRESUMO
This study surveys the development of Alzheimer's disease (AD) in the research literature, the scientific community, and the journals containing AD papers over a 35-year period. Research papers on AD published from 1983 to 2017 in journals indexed in the Web of Science were analyzed in seven five-year periods. The number of AD papers increased from 1,095 in 1983-1987 to 50,532 by 2013-2017 and in the same time period, the number of participating countries went from 27 to 152. The US was the most prolific country throughout, followed by several European countries, Canada, Australia, and Japan. Asian countries have emerged and by 2013-2017, China surpassed all but the US in productivity. Countries in Latin America and Africa have also contributed to AD research. Additionally, several new non-governmental institutions (e.g., ADNI, ADI) have emerged and now play a key role in the fight against AD. Likewise the AD scientific publishing universe evolved in various aspects: an increase in number of journals containing AD papers (227 journals in 1983-1987 to 3,257 in 2013-2017); appearance of several AD-focused journals, e.g., Alzheimer's & Dementia, Journal of Alzheimer's Disease; and the development of special issues dedicated to AD. Our paper complements the numerous extant papers on theoretical and clinical aspects of AD and provides a description of the research landscape of the countries and journals contributing papers related to AD.
Assuntos
Doença de Alzheimer , Bibliometria , Publicações Periódicas como Assunto , Doença de Alzheimer/história , Doença de Alzheimer/fisiopatologia , História do Século XX , História do Século XXI , Humanos , Revisão da Pesquisa por ParesAssuntos
Doenças Neurodegenerativas/história , Neurociências/história , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/história , Desenvolvimento de Medicamentos/história , Inglaterra , História do Século XX , História do Século XXI , Humanos , Doenças Neurodegenerativas/tratamento farmacológico , Retratos como AssuntoRESUMO
The aim of this work is to describe the history of dementia and Alzheimer's disease (AD) concepts, from early descriptions in antiquity, through studies and authors from different historical periods throughout the centuries, to the latest updates of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). The article also presents the inclusion of the biomarkers from the cerebrospinal fluid, such as Tau and phosphorylated Tau proteins and beta-amyloid peptide in the most recent diagnostic criteria. A literature search was carried out in order to construct a reflexive narrative review of studies dated up to 2015 in the LILACS and Medline databases and with the inclusion of bibliographical references of the area. The different terms used throughout the history of the dementia and Alzheimer's disease concepts were contextualized according to the scientific perspective of a given epoch and its way of producing and reproducing knowledge. The concepts of dementia and AD continue to evolve, largely due to their complexity. Considering the importance and the growth of AD cases in the last and the next decades, this review may contribute in practice with the historical knowledge of the concepts related to dementia and AD.
Assuntos
Doença de Alzheimer/história , Demência/história , Neurologia/história , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/epidemiologia , Doença de Alzheimer/terapia , Demência/diagnóstico , Demência/epidemiologia , Demência/terapia , História do Século XV , História do Século XVI , História do Século XVII , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , História Antiga , História Medieval , Humanos , Neurologia/métodos , Neurologia/tendênciasRESUMO
According to the World Health Organization (WHO), dementia is a disorder that occurs as result of a neurodegenerative process in brain, and usually is chronic or progressive by nature. Most descriptions of senile dementia date back to Alois Alzheimer. In 1906, Alzheimer described the first patient, Auguste Deter, who suffered from the disorder that later became known as Alzheimer's disease. Although, the history of the disease before 1906 is quite rich, little has been said about the contributions of ancient and medieval physicians to the understanding of dementia. Over the centuries, the concept of senile dementia changed from an inevitable mental decline with aging, to different sets of clinical features with narrow limits of diagnosis of a disease in its own right. Documentation of the historical origins of prevention, diagnosis, and therapies of dementia would make an important contribution to a more complete understanding of this pathological degeneration of dementia. The present review focuses on the contributions of Avicenna (AD 980-1037) to the development of diagnosis and the discovery of etiology of different forms of dementia, with the goal of revealing the extent to which dementia was understood in the golden age of Islam in Persia.
Assuntos
Doença de Alzheimer , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/história , Doença de Alzheimer/psicologia , História Medieval , Humanos , PérsiaRESUMO
After World War I and more particularly in June 1940, the prestige of French Marshal Philippe Pétain, considered as the winning general the battle of Verdun, was very high. He became President of Council while the French army was unable to stop the German offensives. But five years later he was sentenced to death for high treason. By rereading his bibliography from a medical perspective, it is possible to find multiple suggestive events and to affirm a posteriori Pétain suffered from a neurodegenerative disorder, whose first signs appeared in the 1930s, suggestive of Alzheimer's disease, which had an impact on French politics. The modern medical knowledge of this disease casts a new light on the behavior of Petain during the last war.
Assuntos
Doença de Alzheimer/história , Militares/história , II Guerra Mundial , I Guerra Mundial , História do Século XIX , História do Século XX , Humanos , MasculinoRESUMO
Dr. Robert Terry (January 14, 1924-May 20, 2017) studied normal aging and Alzheimer's disease for more than five decades. He was at a visionary neuropathologist who trained generations of researchers in the field of neurodegenerative disorders and was always at the cutting edge of incorporating ever advancing technology into the fields of neuroscience and neuropathology. He was among the first to study plaques and tangles using electron microscopy, described the effects of aluminum on neurons, and collaborated to develop new approaches to study synaptic pathology in the context of cognitive impairment in Alzheimer's disease. Dr. Terry made indelible contributions to our understanding of Alzheimer's disease and dementia. In memory of Bob: veteran, physician-scientist, collaborator, friend, husband, and father.
Assuntos
Envelhecimento , Doença de Alzheimer , Neuropatologia/história , Neurociências/história , Envelhecimento/patologia , Envelhecimento/psicologia , Doença de Alzheimer/história , Doença de Alzheimer/patologia , Doença de Alzheimer/fisiopatologia , Doença de Alzheimer/psicologia , História do Século XX , Humanos , Pesquisa/história , Estados UnidosRESUMO
The term dementia derives from the Latin root demens, which means being out of one's mind. Although the term "dementia" has been used since the 13th century, its mention in the medical community was reported in the 18th century. Even though the Greeks postulated a cerebral origin, the concept was not restricted to senile dementia and included all sorts of psychiatric and neurological conditions leading to psychosocial consequences. In the 19th century, individuals with dementia were recognized as patients, deserving medical care from specialists called alienists, and senile dementia became a medical disease. Subsequently, progresses in neuropathology allowed its fragmentation into different neuropathological conditions. Senile dementia was considered as a distinct entity from Alzheimer's seminal case published in 1906, and was first attributed to a vascular origin. However, from the late 1960s and for 20 subsequent years, Alzheimer's disease became the prototypical senile dementia. Only recently, the term dementia was abandoned for major neurocognitive disorder and the heterogeneity of the syndrome acknowledged again at the phenotypical and molecular levels. We hope a better understanding of this fascinating history will improve scientific research and impose humility towards the complex underpinnings of age-related cognitive decline.
Assuntos
Doença de Alzheimer/história , Encéfalo/patologia , Demência/história , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/patologia , Encefalopatias/diagnóstico , Encefalopatias/história , Demência/diagnóstico , Demência/etiologia , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , SíndromeRESUMO
The nucleus basalis of Meynert (nbM) was first described at the end of the 19th century and named after its discoverer, Theodor Meynert. The nbM contains a large population of cholinergic neurons that project their axons to the entire cortical mantle, the olfactory tubercle, and the amygdala. It has been functionally associated with the control of attention and maintenance of arousal, both key functions for appropriate learning and memory formation. This structure is well-conserved across vertebrates, although its degree of organization varies between species. Since early in the investigation of its functional and pathological significance, its degeneration has been linked to various major neuropsychiatric disorders. For instance, Lewy bodies, a hallmark in the diagnosis of Parkinson's disease, were originally described in the nbM. Since then, its involvement in other Lewy body and dementia-related disorders has been recognized. In the context of recent positive outcomes following nbM deep brain stimulation in subjects with dementia-associated disorders, we review the literature from an historical perspective focusing on how the nbM came into focus as a promising therapeutic option for patients with Alzheimer's disease. Moreover, we will discuss what is needed to further develop and widely implement this approach as well as examine novel medical indications for which nbM deep brain stimulation may prove beneficial.
Assuntos
Núcleo Basal de Meynert , Transtornos Cognitivos/terapia , Estimulação Encefálica Profunda , Doença de Alzheimer/história , Doença de Alzheimer/terapia , Núcleo Basal de Meynert/anatomia & histologia , Núcleo Basal de Meynert/fisiologia , Transtornos Cognitivos/história , Estimulação Encefálica Profunda/história , História do Século XIX , História do Século XX , História do Século XXI , HumanosRESUMO
The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of ß-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure ß-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.
Assuntos
Doença de Alzheimer/história , Terminologia como Assunto , Doença de Alzheimer/diagnóstico , História do Século XX , História do Século XXI , HumanosRESUMO
What is Alzheimer's: an organic, neuropathological psychiatric disease, caused by plaques and tangles in aging brains or/and an existential condition affecting the minds of aging persons experiencing disconnection from meaning-bearing networks of social relations? Reviewing current research and revisiting Alzheimer's original case of 'Auguste D' this paper offers an historical-sociological genealogy that raises fundamental questions of causality, and even of the ontological status of Alzheimer's and the dementia reputed to it as a disease entity. Drawing on Kuhn's notion of 'science as usual' and Foucault's notion of the discursive formation of 'regimes of truth', our analysis seeks to understand how a sole medical focus on either bio-markers of neurological disease or genetic association was accomplished in the absence of sufficient and robust evidence. To counter the exclusion of psychosocial considerations, this paper offers two original hypotheses on the iconic case of 'Auguste D', taking into account the social milieu in which she lived and the specific circumstances of her life. It goes on to suggest the way in which the contemporary socio-cultural context may have dementiagenic tendencies. This research supports Gaines and Whitehouse's argument that research into the phenomenon and symptoms of Alzheimer's should focus on extracorporal and psychosocial factors.